Molecularly targeted therapies for metastatic triple-negative breast cancer.

PubWeight™: 1.21‹?› | Rank: Top 10%

🔗 View Article (PMID 23358903)

Published in Breast Cancer Res Treat on January 29, 2013

Authors

Soley Bayraktar1, Stefan Glück

Author Affiliations

1: Department of Medical Oncology, Mercy Cancer Center, Ardmore, OK, USA. soley.bayraktar@gmail.com

Articles citing this

Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol (2013) 1.49

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget (2014) 1.34

Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget (2014) 1.28

Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer. J Surg Sci (2013) 1.10

MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis (2014) 1.02

The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis (2015) 0.96

Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β-tubulin. J Biol Chem (2013) 0.93

HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells. Int J Biol Sci (2015) 0.92

The La-Related Proteins, a Family with Connections to Cancer. Biomolecules (2015) 0.88

Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis (2013) 0.86

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol (2014) 0.84

Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis (2014) 0.84

Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am J Pathol (2014) 0.82

Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prev Res (Phila) (2014) 0.80

Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer. Oncotarget (2014) 0.79

Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice. PLoS One (2014) 0.79

The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. Int J Oncol (2015) 0.78

SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Res (2016) 0.78

Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets. Medicine (Baltimore) (2016) 0.77

Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells. BMC Cancer (2014) 0.77

Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. BMC Cancer (2015) 0.76

Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry. J Breast Cancer (2014) 0.76

Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. Breast Cancer Res Treat (2016) 0.75

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. Oncoscience (2016) 0.75

Combined phosphoproteomics and bioinformatics strategy in deciphering drug resistant related pathways in triple negative breast cancer. Int J Proteomics (2014) 0.75

Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis. Cell Death Dis (2016) 0.75

Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle. J Nanomed Nanotechnol (2016) 0.75

A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer. Oncotarget (2017) 0.75

Articles by these authors

How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol (2006) 1.81

Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med (2008) 1.27

Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26

Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23

Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17

A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer (2009) 1.14

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14

Participation in cancer clinical trials: why are patients not participating? Med Decis Making (2013) 1.10

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05

Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res (2006) 1.02

Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer (2006) 1.01

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95

Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat (2012) 0.95

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol (2011) 0.90

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat (2011) 0.90

Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida. Int J Behav Med (2014) 0.89

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol (2014) 0.86

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs (2013) 0.85

Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85

A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84

Chemoprevention of breast cancer. Expert Rev Anticancer Ther (2008) 0.84

Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol (2010) 0.83

Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83

Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert Opin Ther Targets (2012) 0.83

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol (2012) 0.83

Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells (2005) 0.82

Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat (2014) 0.81

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat (2010) 0.79

Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med (2016) 0.78

Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78

Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep (2012) 0.77

Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77

Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol (2004) 0.77

Introduction to special issue translational goals of neoadjuvant therapy. Breast Cancer Res Treat (2012) 0.75

Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Clin Adv Hematol Oncol (2008) 0.75

Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro. Stem Cells Dev (2004) 0.75

Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers (2013) 0.75